Oneness Biotech Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: Taiwan
Identifier: ROCO:4743
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The company's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, OB318, and others. Along with its subsidiaries, the company operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation segment.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 87 out of 843
Universe
Global Universe 4171 out of 14640
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Oneness Biotech Co., Ltd. |
20.2
Medium
|
87 out of 843 |
| Towa Pharmaceutical Co., Ltd. |
28.9
Medium
|
336 out of 843 |
| Cosmo Pharmaceuticals NV |
29.4
Medium
|
359 out of 843 |
| Guizhou Xinbang Pharmaceutical Co., Ltd. |
35.2
High
|
620 out of 843 |
| Torii Pharmaceutical Co., Ltd. |
35.4
High
|
634 out of 843 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
